Viatris launches RYZUMVl 0.75% in US
The average time of dilation lasts three to eight hours
The average time of dilation lasts three to eight hours
This acquisition enables MTD to open new, strategic markets
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
For the treatment of stenotic lesions of arteriovenous fistula in the haemodialysis management of chronic renal failure
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations
The CRDMO site will add 120,000L manufacturing capacity to WuXi Biologics’ global network
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
The surgeons were able to remove the entire breast while preserving the nipple through tiny hidden incisions
WINREVAIR is a breakthrough biologic for this rare, progressive disease
Subscribe To Our Newsletter & Stay Updated